Skip to content

#恒瑞

Today 0 items
Oct 9Fri
  1. biopharmadive.com61

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    Viatris is buying Pacira BioSciences for $1.65 billion, paying $36.50 per share in cash, a 45% premium, to gain the non-opioid pain drugs Exparel and Zilretta for post-surgical and osteoarthritis knee pain. Pacira's two main products booked $692 million in sales in 2025, up about 4% from 2024. The deal is expected to close by the end of 2026, with generics for Exparel likely from early 2030 and Zilretta patents expiring in 2031.

    Why it matters: Large-cap pharma M&A in pain therapeutics, with near-term patent cliffs on the acquired products.

Oct 1Thu
  1. BioCentury66

    Novo gets shot at weekly obesity pill as Hengrui gets another MNC deal

    Novo Nordisk has in-licensed ex-China rights to a once-weekly oral dual agonist of GLP1R and GIPR from Jiangsu Hengrui Pharmaceuticals for $300 million up front, in one of the largest preclinical deals to date. The compound is intended for obesity, a core therapeutic area Novo Nordisk is building out through a series of deals this year. Hengrui continues its run of MNC partnerships.

    Why it matters: Large preclinical licensing deal with $300 million up front strengthens Novo Nordisk's obesity pipeline.

Sep 30Wed
  2. biopharmadive.com41

    Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

    Novo Nordisk is paying Hengrui Pharma $300 million up front and up to $2.6 billion in milestones for rights to HRS-1596, a once-weekly oral obesity drug that acts on GLP-1 and GIP. Novo gains rights outside China, Taiwan and nearby territories, aiming to challenge Eli Lilly's Zepbound. Described as Phase 1 ready, the drug has not been tested in humans and could be years from regulatory clearance.

Sep 29Tue
  1. statnews.com43

    STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

    AstraZeneca has invested $2 billion in Summit Therapeutics, according to the headline of a STAT+ report. Separately, Novo Nordisk licensed a once-weekly oral GLP-1/GIP receptor agonist for obesity from Hengrui Pharma, paying $300 million upfront for global rights outside China, with total deal value of $2.6 billion if milestones are met; the drug is ready for Phase 1 development.

    Why it matters: AstraZeneca's $2 billion Summit stake and Novo's $2.6 billion obesity drug deal both move competitive pharma positioning.

  2. biospace.com45

    Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal

    Novo Nordisk is licensing HRS-1596, Hengrui Pharma's once-weekly oral GLP-1R/GIPR dual agonist ready for Phase 1, paying $300 million upfront with the deal worth up to $2.6 billion in milestones plus royalties. The asset is intended for obesity, type 2 diabetes and other metabolic diseases, and China has already cleared it for a Phase 1 study in weight management and T2D. BMO Capital Markets says the deal is unlikely to change near-term competition but once-weekly oral dosing could offer longer-term differentiation.

  3. bsky.app42

    Signal or noise? > Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical

    Novo has agreed a deal worth $2.6 billion with Hengrui for a preclinical GLP-1/GIP drug. Hengrui is described as an in-demand partner in the obesity and metabolic space. No further deal terms or timelines are given.

    Why it matters: Large licensing sum for a preclinical asset signals continued competition for GLP-1/GIP pipeline programs.

Aug 17Mon
  1. fiercepharma.com63

    Sandoz strikes $322M biosimilars deal with Shanghai Henlius

    Sandoz has licensed commercialization rights outside China to three Shanghai Henlius biosimilars in early development: versions of Amgen's Repatha, GSK's Benlysta and Eli Lilly and Merck KGaA's Erbitux, which together generated $6.8 billion in sales last year. Sandoz will pay up to $100.5 million up front and up to $322 million with milestones, and the partnership could expand to 10 biosimilars, growing Sandoz's pipeline from 39 to a potential 46. Henlius retains Chinese rights and continues development and manufacturing.

    Why it matters: Large biosimilar licensing deal targeting three blockbuster biologics amid coming patent expiries.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org